Immunic downgraded by SVB Leerink with a new price target
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care
SVB Leerink downgraded Immunic from Outperform to Mkt Perform and set a new price target of $5.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/29/2025 | $13.00 | Buy | Chardan Capital Markets |
| 3/25/2025 | Outperform | William Blair | |
| 11/25/2024 | $10.00 | Buy | H.C. Wainwright |
| 9/9/2024 | $5.00 | Outperform | Leerink Partners |
| 8/27/2024 | $6.00 | Buy | B. Riley Securities |
| 10/21/2022 | $5.00 | Outperform → Mkt Perform | SVB Leerink |
| 9/19/2022 | $26.00 | Buy | H.C. Wainwright |
| 9/7/2021 | $40.00 → $25.00 | Buy | HC Wainwright & Co. |
8-K - IMMUNIC, INC. (0001280776) (Filer)
S-8 - IMMUNIC, INC. (0001280776) (Filer)
SCHEDULE 13G/A - IMMUNIC, INC. (0001280776) (Subject)
NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in October: October 4-7: UEGW 2025 – United European Gastroenterology Week. Immunic's R&D team will attend this conference in Berlin, Germany. Data on IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), will be presented in an oral presentation, a publication, and an ePoster, all of which will be accessible on the "Events and Presentat
– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over Placebo in the Overall Study Population and Consistent Effects Across Subtypes – – CALLIPER Data Showed Positive and Consistent Signals for Slowing Disability Progression Across Disability Endpoints, Patient Populations and Subgroups Without Evidence of Focal Inflammation, Reinforcing the Drug's Neuroprotective Potential and Promise to Slow Disease Progression – – CALLIPER Data Supports Nurr1 Activation as New Mechanism to Prevent Neurodegeneration in Multiple Sclerosis – – Long-Term Data From P
– Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Comprehensive Intellectual Property Strategy Secures Protection Into 2041 in the U.S., Unless Extended Further – NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/529,946, entitled, "Treatment of multiple sclerosis comprising DHODH inhibitors." Specifically, the resulting patent covers dose stren
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4/A - IMMUNIC, INC. (0001280776) (Issuer)
4/A - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
Chardan Capital Markets initiated coverage of Immunic with a rating of Buy and set a new price target of $13.00
William Blair initiated coverage of Immunic with a rating of Outperform
H.C. Wainwright initiated coverage of Immunic with a rating of Buy and set a new price target of $10.00
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered,
– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea
– Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Mr. Tardio will lead in
– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr
– Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro
– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)